Herzlichen Glückwunsch zu China-Lutongs erfolgreicher
Fertigstellung der AUTOMEC 2017, einer der führenden Messen in Lateinamerika für Automotive Aftermarket-Industrie.
China Lutong Parts Plant is a
professional OEM & Aftermarket parts supplier, which specialized in diesel engine parts.
Our main products include Control Valve, Injectors,common rail valve, Head rotor, plunger
barrel,(VE Pump Parts), Injector Nozzle, Plunger, Delivery Valve , Injectors, Cam Disk, Repair
Kits, Feed Pump and more.
Diese Ausstellung brachte
aus aller Welt namhafte Unternehmen wie Bosch,Delphi,
Denso, Lucas zusammen. Und es wurde eine einmalige Gelegenheit, mit den
Entscheidungsträgern auf dem Markt Geschäfte zu machen.
In dieser Ausstellung
erhielt China Lutong neue und alte Gäste aus Brasilien, sowie andere Länder in
Südamerika, Chile, Peru und
Argentinien usw. Zu dieser Zeit präsentieren wir unsere repräsentativen
VE-Pumpenteile und unsere neue Forschung wie die Kontrolle Ventile (9308-621B /
9308-622B / CAT (C7, C9) / Volvo (7206-0379)), Denso und Bosch Common Rail
Injektoren (095000-5471,).
China-Lutong-Maschinen-Werk
Co., Ltd. Hoffe, eine gute und langfristige Geschäftsbeziehung mit Ihnen zu
etablieren.
AUTOMEC 2017 (Sao
Paulo-Brasilien)
Stand Nr. EE266
Datum 25 -29 April 2017
Lage Sao Paulo Expo
Ausstellung & Kongresszentrum
Influenza Vaccine
Influenza Vaccine, Live, Nasal, Freeze-dried Exclusively authorized by the WHO in China WHO
Influenza Vaccine, Live, Nasal, Freeze-dried is a cooperative project with the WHO, which has been included in Global Action Plan for Influenza Vaccines (GAP)[1]. Hundreds of millions of doses have been used in the world, and Changchun BCHT Biotechnology Co. has the exclusive right of production and
operation in China.
Intranasal spray administration, no injection and no pain
The vaccine is inoculated by nasal spray, equipped with nasal spray device, and only needs to spray once a year in two nostrils to prevent influenza.
Mucosal immunity + Cellular immunity + Humoral immunity
After influenza virus attacks human body, it widely exists in nasal cavity, respiratory tract and other mucosal parts, as well as in body fluids and cells.
Vaccination of Influenza Vaccine, Live, Nasal, Freeze-dried can quickly stimulate the triple immune response of human body, and carry out defense
against viruses in different parts:
·Intranasal administration can produce mucosal immunity (IgA antibody), which forms the first immune defense line in the nasal cavity.
·Produce humoral immunity (IgG antibody) to remove influenza virus from body fluids.
·Produce cellular immunity (T cells) to remove influenza virus from cells
3+N More extensive protection
The production strains are recommended and supplied by the WHO every year.
The vaccine can not only effectively resist the vaccine strain, but also produce cross immunity to other subtypes of influenza virus.
Produced with SPF embryonated eggs
The chick embryos for vaccine production comes from SPF (specific pathogen free) chicken flocks, so the risk of exogenous pathogenic microorganism
pollution is excluded.
Free of inactivator, split agent and preservative
High protection and fast antibody production
This is the first influenza vaccine in China that has been evaluated by the protection effect of etiology in clinical stage. The protective effect of phase III
clinical trial is consistent with the literature[2]
.
First, the immune barrier was formed in the nasal mucosa after LAIV vaccination. It has been reported that the antibody of nasal mucosa can be
produced in 3 days[3], which greatly shortens the time for vaccine to produce
protective effect.
Influenza Vaccine,Influenza Vaccine Development,Influenza Vaccine Strains,Flu Vaccine
Changchun BCHT Biotechnology Co. , https://www.ccbcht.net